Beigene logo

BGNE - Beigene News Story

$305.4 -4.9  -1.6%

Last Trade - 05/05/21

Sector
Healthcare
Size
Large Cap
Market Cap £20.68bn
Enterprise Value £17.70bn
Revenue £222.5m
Position in Universe 446th / 6846

BRIEF-Beigene Provides Update On Phase 2 Clinical Trial Of Zanubrutinib In Patients With Covid-19-Related Pulmonary Distress

Thu 8th April, 2021 12:10pm
April 8 (Reuters) - Beigene Ltd  6160.HK :
    * BEIGENE PROVIDES UPDATE ON PHASE 2 CLINICAL TRIAL OF
ZANUBRUTINIB IN PATIENTS WITH COVID-19-RELATED PULMONARY
DISTRESS
    * BEIGENE LTD - TRIAL DID NOT MEET CO-PRIMARY EFFICACY
ENDPOINTS;
NO NEW SAFETY SIGNALS IDENTIFIED
    * BEIGENE LTD - THERE WERE NO NEW OR ADDITIONAL SAFETY
SIGNALS FOR
ZANUBRUTINIB IDENTIFIED IN TRIAL

Source text for Eikon:  ID:nBw8Q6LGya 
Further company coverage:  6160.HK 

 ((Reuters.Briefs@thomsonreuters.com;))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.